XML 47 R7.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (20,027,000) $ (15,788,000) $ (12,088,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 7,000 10,000 12,000
Stock-based compensation expense 3,400,000 4,070,000 3,789,000
Loss from equity method investment in Galectin Sciences LLC   400,000  
Changes in operating assets and liabilities:      
Prepaid expenses and other assets (21,000) (335,000) (39,000)
Accounts payable and accrued expenses (Notes 2 and 8) (342,000) (783,000) 848,000
Other long-term liabilities     (6,000)
Net cash used in operating activities (16,983,000) (12,426,000) (7,484,000)
CASH FLOWS FROM INVESTING ACTIVITIES:      
Equity method investment in Galectin Sciences LLC   (400,000)  
Purchases of property and equipment 0 0 0
Change in restricted cash and security deposit 0 0 0
Net cash used in investing activities   (400,000)  
CASH FLOWS FROM FINANCING ACTIVITIES:      
Net proceeds from issuance of common stock and warrants 13,701,000 29,337,000 3,833,000
Net proceeds from exercise of common stock warrants and options   2,128,000 4,776,000
Net cash provided by financing activities 13,701,000 31,465,000 8,609,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (3,282,000) 18,639,000 1,125,000
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 29,128,000 10,489,000 9,364,000
CASH AND CASH EQUIVALENTS, END OF PERIOD 25,846,000 29,128,000 10,489,000
NONCASH FINANCING ACTIVITIES:      
Payment of preferred stock dividends in common stock $ 868,000 $ 943,000 $ 867,000